Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors
Jeffrey S. Miller, Chihiro Morishima, Douglas G. McNeel, et al.
Clinical Cancer Research (2017) Vol. 24, Iss. 7, pp. 1525-1535
Open Access | Times Cited: 172

Showing 26-50 of 172 citing articles:

Molecular Aspects and Future Perspectives of Cytokine-Based Anti-cancer Immunotherapy
Daria S. Chulpanova, Kristina V. Kitaeva, Andrew R. Green, et al.
Frontiers in Cell and Developmental Biology (2020) Vol. 8
Open Access | Times Cited: 92
A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells
Upasana Sunil Arvindam, P.M.M. van Hauten, Dawn K. Schirm, et al.
Leukemia (2020) Vol. 35, Iss. 6, pp. 1586-1596
Open Access | Times Cited: 80
NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo
Daniel A. Vallera, Soldano Ferrone, Behiye Kodal, et al.
Cancers (2020) Vol. 12, Iss. 9, pp. 2659-2659
Open Access | Times Cited: 77
Interleukin-15 and cancer: some solved and many unsolved questions
Piera Filomena Fiore, Sabina Di Matteo, Nicola Tumino, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 2, pp. e001428-e001428
Open Access | Times Cited: 72
Next-generation cytokines for cancer immunotherapy
Diyuan Xue, Eric J. Hsu, Yang‐Xin Fu, et al.
Antibody Therapeutics (2021) Vol. 4, Iss. 2, pp. 123-133
Open Access | Times Cited: 61
NK Cell Therapy: A Rising Star in Cancer Treatment
Nawen Du, Feifei Guo, Yufeng Wang, et al.
Cancers (2021) Vol. 13, Iss. 16, pp. 4129-4129
Open Access | Times Cited: 60
Interleukin 15 in Cell-Based Cancer Immunotherapy
Yang Zhou, Tiffany Husman, Xinjian Cen, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 13, pp. 7311-7311
Open Access | Times Cited: 58
Overcoming tumor resistance mechanisms in CAR-NK cell therapy
Antonio Valeri, Almudena García-Ortiz, Eva Castellano, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 56
Immunotherapy in non-small cell lung cancer: Past, present, and future directions
Salman R. Punekar, Elaine Shum, Cassandra Mia Grello, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 56
Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy
Shweta Joshi, Andrew B. Sharabi
Pharmacology & Therapeutics (2022) Vol. 235, pp. 108114-108114
Open Access | Times Cited: 52
Research progress of interleukin-15 in cancer immunotherapy
Menghan Cai, Xuan Huang, Xiting Huang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 35
Recent advances and remaining challenges in lung cancer therapy
Tasha Barr, Shoubao Ma, Zhixin Li, et al.
Chinese Medical Journal (2024) Vol. 137, Iss. 5, pp. 533-546
Open Access | Times Cited: 13
NK cell-based therapeutics for lung cancer
A. Graham Pockley, Peter Vaupel, Gabriele Multhoff
Expert Opinion on Biological Therapy (2019) Vol. 20, Iss. 1, pp. 23-33
Closed Access | Times Cited: 70
Role of natural killer cells in lung cancer
Ozge Nur Aktaş, Ayşe Bilge Öztürk, Baran Erman, et al.
Journal of Cancer Research and Clinical Oncology (2018) Vol. 144, Iss. 6, pp. 997-1003
Open Access | Times Cited: 66
Rationale for IL-15 superagonists in cancer immunotherapy
Karin M. Knudson, James W. Hodge, Jeffrey Schlom, et al.
Expert Opinion on Biological Therapy (2020) Vol. 20, Iss. 7, pp. 705-709
Open Access | Times Cited: 63
Potent Cytolytic Activity and Specific IL15 Delivery in a Second-Generation Trispecific Killer Engager
Martin Felices, Todd Lenvik, Behiye Kodal, et al.
Cancer Immunology Research (2020) Vol. 8, Iss. 9, pp. 1139-1149
Open Access | Times Cited: 55
Bi-specific and Tri-specific NK Cell Engagers: The New Avenue of Targeted NK Cell Immunotherapy
Shee Kwan Phung, Jeffrey S. Miller, Martin Felices
Molecular Diagnosis & Therapy (2021) Vol. 25, Iss. 5, pp. 577-592
Closed Access | Times Cited: 47
Chemokine-Cytokine Networks in the Head and Neck Tumor Microenvironment
Sabah Nisar, Parvaiz Yousuf, Tariq Masoodi, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 9, pp. 4584-4584
Open Access | Times Cited: 45
Harnessing the cDC1-NK Cross-Talk in the Tumor Microenvironment to Battle Cancer
Johanna Bödder, Tasmin Zahan, Rianne van Slooten, et al.
Frontiers in Immunology (2021) Vol. 11
Open Access | Times Cited: 44
Crosstalk between IL‐15Rα+tumor‐associated macrophages and breast cancer cells reduces CD8+T cell recruitment
Wenlong Zhang, Qing Zhang, Nanfei Yang, et al.
Cancer Communications (2022) Vol. 42, Iss. 6, pp. 536-557
Open Access | Times Cited: 35
Emerging Strategies in TCR-Engineered T Cells
Wei Fang, Xiao-Xia Cheng, John Z. Xue, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 34
Immunotherapy in head and neck squamous cell carcinoma: An updated review
Kanak Parmar, Abdallah Mohamed, E. Vaish, et al.
Cancer Treatment and Research Communications (2022) Vol. 33, pp. 100649-100649
Open Access | Times Cited: 32
Exercise-induced IL-15 acted as a positive prognostic implication and tumor-suppressed role in pan-cancer
Zhiwen Luo, Zhong He, Haocheng Qin, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 29
Facts and Hopes on Chimeric Cytokine Agents for Cancer Immunotherapy
Zhenhua Ren, Xuhao Zhang, Yang‐Xin Fu
Clinical Cancer Research (2024) Vol. 30, Iss. 10, pp. 2025-2038
Closed Access | Times Cited: 7
Natural killer cells in cancer immunotherapy
Danru Wang, LingYun Dou, Lihao Sui, et al.
MedComm (2024) Vol. 5, Iss. 7
Open Access | Times Cited: 6

Scroll to top